ArticleLupus science & medicine2025
Vitamin D receptor expression level in patients with SLE and its relationship with vitamin D status, disease course and bone mineral density.
Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cannabinoid receptor expression profiling in lymphocyte subsets reveals clinically relevant immune patterns in SLE.Frontiers in immunology · 2026Article
- Combined assessment of 25(OH)D, CD4Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine vitamin D receptor (VDR) blood serum concentrations in patients with SLE and to assess the relationship with vitamin D status, disease course, bone turnover markers levels and bone mineral density (BMD).
methodsThe cross-sectional study involved 99 patients with SLE and 30 controls. We assessed VDR, vitamin D, C-reactive protein (CRP), interleukin (IL) 6, osteocalcin (OC), C-terminal telopeptide of type I collagen (CTX) concentrations, and erythrocyte sedimentation rate (ESR) in study subjects. Dual-energy X-ray absorptiometry was also performed.
resultsMean VDR levels in patients with SLE and in the control group were 12.78±0.61 ng/mL and 23.12±0.61 ng/mL, accordingly (p<0.01). 77.8% patients with SLE had low VDR concentrations and only 22.2% patients presented relatively normal or high levels. Low VDR levels in patients with SLE were associated with age (p=0.054, r=-0.22). The study did not reveal a relationship between VDR level and sex, disease duration, body mass index (BMI) and cumulative glucocorticoid (GC) dose. No association was found between VDR level and a diagnosed lupus nephritis, creatinine concentration and glomerular filtration rate. The correlation analysis confirmed the association of low VDR level with high disease activity, namely with elevated CRP (r=-0.22), IL-6 (r=-0.21) levels, SLE Disease Activity Index 2000 variant (r=-0.20). VDR concentration was closely associated with vitamin D supply. The average level of vitamin D in patients with low VDR was 33.55% lower than in the group with a relatively normal vitamin concentration (p=0.0001, r=0.47). We revealed a proportional increase of CTX concentration associated with VDR decrease (p<0.05, r=-0.27). No significant difference in average Z-score, T-score and BMD between the groups of patients with SLE with low and relatively normal VDR levels (p>0.05) was found.
conclusionLow VDR concentration is a common phenomenon in patients with SLE associated with age, high disease activity, vitamin D supply and serum CTX concentration. VDR concentration had no significant association with sex, disease duration, cumulative GC dose, BMI, a diagnosed lupus nephritis, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, OC level and BMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.